520

Angina pectoris is the most common manifestation of myocardial ischaemia and is often a consequence of coronary artery disease (CAD). Angina pectoris (Latin for chest pain) is pain that is caused by injury to the heart muscle (myocardium) during times of increased cardiac activity as a result of impaired blood flow and reduced oxygen supply. It is a common disease in the population of our planet. Complications are very dangerous.  This article discusses effective methods of treatment of this disease. 

  • Read count396
  • Date of publication30-01-2021
  • Main LanguageIngliz
  • Pages1-10
Русский

Стенокардия - частое проявление ишемической болезни сердца и часто является результатом проблем с коронарными артериями. Стенокардия (лат. Angina pectoris; лат. Боль в груди) - это боль, которая возникает в результате повреждения сердечной мышцы (миокарда) в периоды повышенной сердечной деятельности в результате нарушения кровотока и снижения поступления кислорода. Это очень опасное заболевание, которое широко распространено среди населения нашей планеты. В этой статье рассматриваются эффективные способы лечения этого заболевания. 

English

Angina pectoris is the most common manifestation of myocardial ischaemia and is often a consequence of coronary artery disease (CAD). Angina pectoris (Latin for chest pain) is pain that is caused by injury to the heart muscle (myocardium) during times of increased cardiac activity as a result of impaired blood flow and reduced oxygen supply. It is a common disease in the population of our planet. Complications are very dangerous.  This article discusses effective methods of treatment of this disease. 

Ўзбек

 Stenokardiya yurak ishemik kasalligining keng tarqalgan ko'rinishi va ko'pincha koronar arteriya bilan bog'liq muammolar natijasi hisoblanadi. Stenokardiya (Angina pectoris; lotincha ko'krak qafasi og'rig'i) - qon oqimining buzilishi va kislorod bilan ta'minlanishning pasayishi natijasida yurak faoliyati kuchaygan paytlarda yurak muskuli (miokard) shikastlanishidan kelib chiqadigan og'riq. Bu sayyoramiz aholisida keng tarqalgan juda xavfli kasallik. Maqolada ushbu kasallikni davolashning effektiv usullari haqida muhokama qilinadi.

№ Name of reference
1 1. Chong, C.-R., Ong, G. J., & Horowitz, J. D. (2016). Emerging drugs for the treatment of angina pectoris. Expert Opinion on Emerging Drugs, 21(4), 365–376. doi:10.1080/14728214.2016.1241231.
2 2. Ong, P., Athanasiadis, A., & Sechtem, U. (2016). Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction. Cardiovascular Drugs and Therapy, 30(4), 351– 356. doi:10.1007/s10557-016-6676-z.
3 3. Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.
4 4. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensinconverting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation. 2004;109:53–8.
5 5. Chen JW1, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974–982.
6 6. Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, Cooper-DeHoff RM, Sopko G, Sharaf BM, Kelsey SF, Merz CN, Pepine CJ. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, lung and blood institute Women's ischemia syndrome evaluation (WISE). Am Heart J. 2011;162:678–84.
7 7. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X. Eur Heart J. 2003;24:1999–2005.
8 8. Fábián E, Varga A, Picano E, Vajo Z, Rónaszéki A, Csanády M. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol. 2004;94:652–5.
9 9. Zhang X1, Li Q, Zhao J, Li X, Sun X, Yang H, Wu Z, Yang J. Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X. Coron Artery Dis. 2014;25:40–4.
10 10. Wang, J., Yu, X., Deng, S., Yuan, H., & Li, H. (2020). Acupuncture on treating angina pectoris. Medicine, 99(2), e18548. doi:10.1097/md.0000000000018548.
11 11. Osler W. Angina pectoris and arteriosclerosis[J]. JAMA 2015;314: 1981
12 12. Li ZJ, Zeng F, Lan L, et al. [Using functional brain imaging technique to study central mechanism of acupuncture therapy for chronic stable angina pectoris in view of heartbrain correlation].[J]. Zhen Ci Yan Jiu 2014;39:337–40.
13 13. Wang M. Acupuncture styles in current practice[M]. Translational Acupuncture Research 2019.
14 14. Yuan W, Wang Q. Perioperative acupuncture medicine: a novel concept instead of acupuncture anesthesia[J]. Chinese Med J 2019;132:707–15.
15 15. Condello G, Chen CY. Fostering the acupuncture practice for health outcomes research: the perspective from Taiwan[J]. J Chin Med Assoc 2019;82:1.
16 16. Spinka F, Aichinger J, Wallner E, et al. Functional status and life satisfaction of patients with stable angina pectoris in Austria[J]. BMJ Open 2019;9:e029661.
17 17. Tzanis G, Palmisano A, Gallone G, et al. The impact of the coronary sinus reducer upon left ventricular function in patients with refractory angina pectoris[J]. Catheter Cardiovasc Interv 2019.
18 18. Zhuang, J., Dai, X., Zhang, H., Chen, Y., Cai, H., Jin, Z., … Chen, B. (2020). A meta-analysis for Kuanxiong Aerosol on the treatment of angina pectoris. The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2020.01.045.
19 19. Qintar M, Supertus JA, Gosch KL, et al. Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease[J]. Eur Heart J Qual Care Clin Outcomes 2016;2(3):208–20.
20 20. Chinese Pharmacists Association, et al. Guidelines for rational drug use for coronary heart disease (2nd edition) [J]. Chin J Adv Med 2018;10(06):130.
21 21. Liu DH, Zeng Y, Liu BC. Adverse reactions to nitroglycerin [J]. Strait Pharmaceut J 2005;17(6):180–2.
22 22. Guo SK, Chen KJ, Weng WL, et al. Immediate effect of Kuanxiong Aerosol in the treatment of anginal attacks[J]. Planta Med 1983;47(2):116.
23 23. Rakhimov, K., & Gori, T. (2020). Non-pharmacological Treatment of Refractory Angina and Microvascular Angina. Biomedicines, 8(8), 285. doi:10.3390/biomedicines8080285.
Waiting